sarcoidosi
incur
chronic
granulomat
diseas
primarili
involv
lung
lymph
node
unknown
etiolog
treat
nonspecif
antiinflammatoryimmunosuppress
drug
persist
symptomat
patient
worsen
disabl
potenti
fatal
clinic
cours
determin
possibl
infecti
caus
correl
case
control
studi
clinic
inform
presenc
bacteri
dna
sarcoidosi
mediastin
lymph
node
compar
control
lymph
node
resect
cancer
surgeri
retrospect
studi
formalinfix
paraffinembed
mediastin
lymph
node
sarcoidosi
patient
control
lung
cancer
patient
nucleic
acid
extract
node
evalu
rrna
pcr
bacteri
rdna
result
sequenc
compar
bacteri
sequenc
librari
clinic
inform
correl
lymph
node
sarcoidosi
patient
detect
bacteri
dna
significantli
control
patient
lymph
node
p
present
sarcoidosi
patient
symptomat
includ
patient
detect
bacteri
dna
radiograph
stage
stage
ii
patient
stage
ii
patient
symptomat
pcrdetect
bacteria
mean
followup
month
patient
pcrdetect
bacteria
persist
symptomat
requir
treatment
discuss
sarcoidosi
patient
detect
bacteria
dna
present
quit
symptomat
radiographicallyadvanc
stage
ii
patient
find
suggest
bacteri
dnaposit
symptomat
patient
aggress
sarcoidosi
common
yet
incur
chronic
granulomat
diseas
unknown
etiolog
treat
nonspecif
antiinflammatori
andor
immunosuppress
drug
persist
symptomat
patient
worsen
despit
treatment
disabl
potenti
fatal
clinic
cours
propos
sarcoidosi
result
chronic
granulomat
infect
treatabl
pathogen
certain
suscept
individu
much
like
granulomat
ileiti
crohn
diseas
show
encourag
respons
multidrug
antimicrobi
therapi
casecontrol
retrospect
studi
correl
clinic
outcom
presenc
detect
bacteri
dna
sarcoidosi
lymph
node
versu
control
lymph
node
entir
group
sarcoidosi
patient
significantli
detect
bacteri
dna
control
patient
lymph
node
howev
persist
symptomat
patient
detect
bacteri
dna
lymph
node
suggest
aggress
sarcoidoisi
nevertheless
molecular
approach
bacteri
detect
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
imbed
process
postembed
handl
process
paraffin
block
addit
number
lymph
node
posit
bacteri
dna
may
significantli
underestim
tendenc
formalinfix
paraffin
embed
process
breakdown
prokaryot
dna
sarcoidosi
multisystem
granulomat
diseas
whose
etiolog
obscur
controversi
nevertheless
condit
rel
common
significantli
higher
ageadjust
annual
incid
africanamerican
case
per
versu
caucasianamerican
case
per
estim
one
million
peopl
u
diseas
base
current
us
popul
approxim
new
case
sarcoidosi
year
die
ill
fundament
patholog
abnorm
diseas
format
noncas
epitheliod
granuloma
usual
confin
poorli
solubl
foreign
materi
simpli
remov
singl
phagocyt
cell
key
featur
sarcoidosi
activ
cell
differenti
type
helper
cell
secret
augment
macrophag
amplifi
local
cellular
immun
respons
granulomat
inflamm
interfer
local
tissu
homeostasi
lead
organ
impair
sinc
sarcoidosi
primarili
involv
lung
eye
skin
attent
focus
airborn
environment
antigen
might
trigger
presum
hypersensit
respons
cellmedi
cellular
immun
respons
similar
granulomat
respons
seen
varieti
infecti
agent
includ
mycobacteria
parasit
schistosoma
fungi
coccidiomycosi
earli
studi
report
associ
noninfect
agent
includ
beryllium
zirconium
aluminum
woodburn
stove
tree
pollen
clay
soil
talc
insecticid
inorgan
particl
moldi
environ
none
theoret
caus
endur
also
severalfold
increas
incid
sarcoidosi
occur
sibl
parent
well
consist
strong
associ
specif
gene
product
class
class
ii
hla
antigen
may
add
famili
connect
although
infecti
agent
cultur
directli
sarcoidosi
tissu
clinic
immunolog
characterist
disord
provid
strongest
support
microbi
etiolog
least
patient
explor
possibl
infecti
caus
patient
seen
moffitt
cancer
center
correl
clinic
present
longterm
followup
sarcoidosi
patient
presenc
bacteri
dna
archiv
surgicallyresect
mediastin
lymph
node
result
sarcoidosi
node
compar
control
lymph
node
resect
time
lung
surgeri
nodeneg
stage
nonsmal
cell
lung
cancer
patient
tissu
clinic
data
casecontrol
studi
obtain
approv
moffitt
cancer
center
scientif
review
committe
protocol
mcc
univers
south
florida
irb
protocol
search
moffitt
cancer
center
surgic
patholog
databas
januari
april
retrospect
identifi
randomlychosen
patient
diagnos
sarcoidosi
base
typic
radiograph
clinic
present
histolog
find
noncas
epitheliod
granulomata
lymph
node
obtain
steril
mediastinoscopi
avoid
possibl
microorgan
contamin
endoscop
biopsi
special
stain
microorgan
neg
specimen
inclus
f
r
p
e
e
r
r
e
v
e
w
n
l
group
follow
criteria
use
make
diagnosi
sarcoidosi
chest
radiograph
chest
ct
find
symmetr
mediastin
hilar
adenopathi
without
reticulonodular
infiltr
lung
field
see
figur
perform
pet
scan
demonstr
glucos
avid
enlarg
lymph
node
see
figur
asymptomat
present
typic
symptom
dyspnea
cough
chest
tightnesspain
night
sweat
fever
fatigu
malais
skin
rash
weight
loss
lymph
node
show
histolog
featur
confluent
noncas
granulomata
known
microorgan
caus
granulomata
exclud
histori
cultur
histopatholog
specimen
review
one
us
ps
reconfirm
diagnosi
made
origin
department
pathologist
moffitt
insur
steril
collect
control
specimen
taken
lymph
node
remov
open
thoracotomi
one
us
lr
match
case
randomlychosen
patient
stage
ia
nonsmal
lung
cancer
lymph
node
select
patient
small
peripher
tumor
obstruct
atalectasi
evid
activ
infect
one
us
ps
review
control
lymph
node
histolog
verifi
metastas
acut
inflamm
granulomata
clinic
data
patient
demograph
initi
present
symptom
object
find
extract
electron
medic
record
sarcoidosi
patient
one
us
lr
patient
stage
use
modifi
scad
radiograph
stage
system
stage
normal
chest
xray
stage
hilar
mediastin
adenopathi
alon
stage
adenopathi
pulmonari
infiltr
stage
pulmonari
infiltr
alon
stage
pulmonari
fibrosi
longterm
followup
clinic
statu
subsequ
treatment
regimen
sarcoidosi
patient
deidentifi
formalinfix
paraffinembed
block
lymph
node
sarcoidosi
control
patient
sent
depart
laboratori
medicin
microbiolog
univers
washington
seattl
wa
investig
blind
ident
specimen
dna
extract
paraffinembed
block
perform
paraffin
remov
incub
xylen
gene
fragment
amplifi
previous
describ
gene
amplifi
use
primer
rna
polymeras
subunit
gene
rpob
amplifi
use
mf
mr
primer
amplifi
product
sequenc
use
big
dye
sequenc
kit
appli
biosystem
foster
citi
ca
use
vendor
recommend
protocol
sequenc
two
strand
assembl
doubledstrand
contig
use
sequench
softwar
gene
code
ann
arbor
mi
final
sequenc
use
search
nation
center
biotechnolog
inform
nation
institut
health
databas
use
blast
basic
local
align
search
tool
identifi
amplifi
dna
primari
variabl
compar
sarcoidosi
control
patient
number
patient
group
bacteri
dna
found
lymph
node
two
proport
test
compar
independ
proport
small
sampl
size
use
compar
result
two
group
numer
data
express
mean
standard
deviat
demograph
clinic
characterist
sarcoidosi
studi
patient
found
tabl
time
initi
present
patient
symptomat
usual
multipl
symptom
patient
durat
symptom
diagnosi
mean
month
median
month
rang
month
common
symptom
night
sweat
dyspnea
chest
pain
chest
tight
fever
fatigu
skin
rash
stomach
ulcer
symptom
present
least
one
patient
includ
dyspepsia
dysphagia
diarrhea
f
r
p
e
e
r
r
e
v
e
w
n
l
constip
kidney
stone
joint
muscl
pain
orthopnea
nose
mouth
skin
lesion
intermitt
bronchospasm
malais
weight
loss
comorbid
asthma
coronari
arteri
diseas
diabet
mellitu
hypertens
one
gout
hypothyroid
eczema
fibromyalgia
crohn
diseas
malign
extrem
common
half
current
prior
tumor
malign
prior
time
present
breast
melanoma
uterin
sarcoma
tonsil
ovari
adren
colon
hodgkin
lymphoma
chest
figur
typic
exampl
glucos
avid
seen
abnorm
abdomin
node
patient
radiograph
adenopathi
diaphragm
twelv
patient
lymph
node
tissu
sent
time
mediastinoscopi
aerob
fungal
mycobacteri
cultur
cultur
show
growth
six
week
incub
f
r
p
e
e
r
r
e
v
e
w
n
l
node
real
find
studi
prior
publish
studi
process
contamin
therefor
point
microorgan
potenti
contributor
genesi
diseas
addit
propionibacterium
acn
dna
found
control
lymph
node
studi
stark
contrast
ishig
associ
japan
report
microorgan
ubiquit
pulmonari
lymph
node
commens
found
nonsarcoid
patient
studi
high
posit
result
studi
like
due
either
geographicalethicraci
differ
potenti
contamin
process
perhap
intrigu
find
came
correl
pcr
find
clinic
inform
patient
lymph
node
contain
bacteria
dna
present
also
highli
symptomat
poorerprognosi
radiograph
stage
ii
find
moreov
median
year
followup
bacteri
dnaposit
patient
still
highli
symptomat
strike
correl
strongli
suggest
demonstr
bacteri
dna
pcr
lymph
node
initi
present
advers
prognost
factor
make
unlik
patient
spontan
remiss
mani
pathogen
microorgan
tropheryma
whippelii
whippl
diseas
coronavirus
sever
acut
respiratori
syndrom
grown
directli
cultur
slow
grow
fastidi
mycobacterium
lepra
leprosi
instanc
detect
identif
reli
molecular
mechan
pcr
use
studi
nevertheless
molecular
approach
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
imbed
process
postembed
handl
process
paraffin
block
howev
studi
thirti
control
lymph
node
process
ident
manner
bacteri
dna
detect
significantli
less
sarcoidosi
node
p
suggest
contamin
unlik
account
find
addit
number
lymph
node
posit
bacteri
dna
may
significantli
underestim
tendenc
formalinfix
paraffin
embed
process
breakdown
prokaryot
dna
also
time
investig
found
degrad
prokaryot
bacteria
dna
especi
mycobacteria
age
paraffinembed
specimen
note
sarcoidosi
lymph
node
posit
mycobacteria
studi
less
year
old
evalu
pcr
use
fresh
lymph
node
tissu
like
drake
associ
found
pcr
posit
mycobacteria
speci
may
much
higher
rate
posit
bacteri
dna
result
particularli
mycobacteria
studi
sarcoidosi
granulomat
diseas
primarili
involv
lung
lymph
node
organ
appear
result
exuber
cell
macrophag
immunolog
respons
continu
present
poorli
degrad
antigen
numer
noninfect
agent
implic
base
epidemiolog
basi
none
stood
scrutini
focu
last
two
decad
infect
agent
might
trigger
sarcoidosi
strongest
suspect
found
mycobacteria
famili
common
commens
propionibacterium
acn
like
classic
tuberculosi
peopl
infect
mycobacterium
tuberculosi
remain
remiss
without
treatment
sarcoidosi
also
spontan
remiss
rate
without
treatment
one
may
specul
similar
tuberculosi
immun
system
initi
respons
trigger
microorgan
success
erad
agent
immun
respons
subsid
persist
progress
sarcoidosi
organ
remain
viabl
perpetu
destruct
immun
respons
symptomat
sarcoidosi
usual
treat
variou
antiinflammatori
immunosuppress
agent
corticosteroid
methotrex
tnfinhibitor
biolog
similar
immunolog
abnorm
treatment
anoth
debilit
granulomat
diseas
crohn
diseas
strike
granulomat
ileiti
crohn
suspect
mani
investig
result
chronic
infect
oblig
intracellular
microorgan
mycobacterium
avian
subspeci
paratuberculosi
map
known
caus
granulomat
ileiti
cattl
rumin
call
john
diseas
although
classic
treatment
crohn
diseas
immunosuppress
agent
like
sarcoidosi
mani
recent
studi
suggest
much
effect
treatment
less
side
fact
mani
field
suspect
intracellular
organ
map
resid
macrophag
impair
normal
autophagi
would
usual
erad
organ
agent
enhanc
autophagi
current
human
trial
may
prove
effect
along
antibiot
crohn
diseas
antibacterialantimycobacteri
regimen
use
crohn
diseas
alter
natur
histori
sarcoidosi
chronic
symptomat
patient
sixti
year
ago
number
small
trial
use
classic
antitubercul
drug
isoniazid
streptomycin
cortison
publish
discourag
result
howev
atyp
mycobacteria
rather
tuberculosi
like
one
etiolog
agent
sarcoidosi
almost
resist
standard
antituberculosi
agent
isoniazid
organ
proprionibacterium
acn
perhap
cellwal
defici
lform
bacteria
trigger
perpetu
sarcoidosi
individu
standard
antitubercul
drug
would
also
ineffect
tetracyclin
deriv
minocyclin
doxycyclin
well
antimalari
drug
chloroquin
shown
quit
effect
treat
cutan
sarcoidosi
minocyclin
produc
complet
respons
twothird
case
although
debat
whether
antimicrobi
effect
immunomodul
effect
last
three
decad
numer
studi
examin
everi
aspect
sarcoidosi
includ
dysfunct
immun
respons
primari
therapi
immun
author
contributorship
dr
robinson
full
access
data
studi
take
full
respons
integr
data
accuraci
data
analysi
dr
smith
contribut
concept
hypothesi
delin
design
studi
data
acquisit
analysi
interpret
revis
articl
prior
public
dr
sengupta
contribut
data
acquisit
analysi
interpret
revis
articl
prior
public
contribut
data
acquisit
analysi
interpret
dr
sandin
contribut
concept
hypothesi
delin
design
studi
revis
articl
prior
public
data
share
addit
data
avail
financialnonfinanci
disclosur
author
report
potenti
conflict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
materi
result
work
support
resourc
use
facil
articl
focu
sarcoidosi
common
yet
incur
chronic
granulomat
diseas
unknown
etiolog
treat
nonspecif
antiinflammatori
andor
immunosuppress
drug
persist
symptomat
patient
worsen
despit
treatment
disabl
potenti
fatal
clinic
cours
propos
sarcoidosi
result
chronic
granulomat
infect
treatabl
pathogen
certain
suscept
individu
much
like
granulomat
ileiti
crohn
diseas
show
encourag
respons
multidrug
antimicrobi
therapi
casecontrol
retrospect
studi
correl
clinic
outcom
presenc
detect
bacteri
dna
sarcoidosi
lymph
node
versu
control
lymph
node
entir
group
sarcoidosi
patient
significantli
detect
bacteri
dna
control
patient
lymph
node
nevertheless
molecular
approach
bacteri
detect
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
imbed
process
postembed
handl
process
paraffin
block
also
mere
physic
presenc
bacteri
dna
lymph
node
prove
diseas
caus
microorgan
addit
number
lymph
node
posit
bacteri
dna
may
significantli
underestim
tendenc
formalinfix
paraffin
embed
process
breakdown
prokaryot
dna
fundament
patholog
abnorm
diseas
format
noncas
epitheliod
granuloma
usual
confin
poorli
solubl
foreign
materi
simpli
remov
singl
phagocyt
cell
key
featur
sarcoidosi
activ
cell
differenti
type
helper
cell
secret
augment
macrophag
amplifi
local
cellular
immun
respons
granulomat
inflamm
interfer
local
tissu
homeostasi
lead
organ
impair
sinc
sarcoidosi
primarili
involv
lung
eye
skin
attent
focus
airborn
environment
antigen
might
trigger
presum
hypersensit
respons
cellmedi
cellular
immun
respons
similar
granulomat
respons
seen
varieti
infecti
agent
includ
mycobacteria
parasit
schistosoma
fungi
coccidiomycosi
earli
studi
report
associ
noninfect
agent
includ
beryllium
zirconium
aluminum
woodburn
stove
tree
pollen
clay
soil
talc
insecticid
inorgan
particl
moldi
environ
none
theoret
caus
endur
also
severalfold
increas
incid
sarcoidosi
occur
sibl
parent
well
consist
strong
associ
specif
gene
product
class
class
ii
hla
antigen
may
add
famili
connect
although
infecti
agent
cultur
directli
sarcoidosi
tissu
clinic
immunolog
characterist
disord
provid
strongest
support
microbi
etiolog
least
patient
explor
possibl
infecti
caus
patient
seen
moffitt
cancer
center
correl
clinic
present
longterm
followup
sarcoidosi
patient
presenc
bacteri
dna
archiv
surgicallyresect
mediastin
lymph
node
result
sarcoidosi
node
compar
control
lymph
node
resect
time
lung
surgeri
nodeneg
stage
nonsmal
cell
lung
cancer
patient
tissu
clinic
data
casecontrol
studi
obtain
approv
clinic
data
patient
demograph
initi
present
symptom
object
find
extract
electron
medic
record
sarcoidosi
patient
one
us
lr
patient
stage
use
modifi
scad
radiograph
stage
system
stage
normal
chest
xray
stage
hilar
mediastin
adenopathi
alon
stage
adenopathi
pulmonari
infiltr
stage
pulmonari
infiltr
alon
stage
pulmonari
fibrosi
longterm
followup
clinic
statu
subsequ
treatment
regimen
sarcoidosi
patient
gene
fragment
amplifi
previous
describ
gene
amplifi
use
primer
rna
polymeras
subunit
gene
rpob
amplifi
use
mf
mr
primer
amplifi
product
sequenc
use
primari
variabl
compar
sarcoidosi
control
patient
number
patient
group
bacteri
dna
found
lymph
node
two
proport
test
compar
independ
proport
small
sampl
size
use
compar
result
two
group
addit
odd
ratio
confid
interv
calcul
numer
data
express
mean
standard
deviat
comorbid
asthma
coronari
arteri
diseas
diabet
mellitu
hypertens
one
gout
hypothyroid
eczema
fibromyalgia
crohn
diseas
malign
extrem
common
half
current
prior
tumor
find
note
previous
other
malign
prior
time
present
breast
melanoma
uterin
sarcoma
tonsil
ovari
adren
colon
hodgkin
lymphoma
chest
node
see
figur
typic
exampl
glucos
avid
seen
abnorm
abdomin
node
patient
radiograph
adenopathi
diaphragm
twelv
patient
lymph
node
tissu
sent
time
mediastinoscopi
aerob
fungal
mycobacteri
cultur
cultur
show
growth
six
week
incub
object
casecontrol
studi
twofold
evalu
sterilelyresect
lymph
node
document
sarcoidosi
patient
presenc
bacteri
dna
molecular
method
b
correl
result
clinic
characterist
patient
expect
molecular
test
use
pcr
demonstr
onethird
sarcoidosi
patient
evid
bacteri
dna
node
indic
either
past
current
involv
microorgan
percentag
bacteri
dnaposit
specimen
fall
rang
found
numer
prior
publish
studi
last
two
decad
use
variou
methodolog
rang
posit
tabl
furthermor
atyp
mycobacteria
proprionibacterium
acn
repres
almost
dna
identifi
also
consist
find
multipl
prior
studi
tabl
addit
identifi
one
skin
mucou
membran
organ
corynebacterium
propinquum
one
aerob
gram
neg
bacillu
duganella
zoogloeoid
usual
found
aqueou
environ
interestingli
latter
patient
duganella
zoogloeoid
asbesto
technician
origin
tropic
haiti
disclaim
find
dna
microorgan
lymph
node
tell
us
whether
viabl
organ
present
whether
caus
granulomat
reaction
similar
prior
publish
studi
summar
tabl
significantli
less
p
control
lymph
node
resect
time
lung
cancer
surgeri
show
node
real
find
studi
prior
publish
studi
process
contamin
therefor
point
microorgan
potenti
contributor
genesi
diseas
addit
propionibacterium
acn
dna
found
control
lymph
node
studi
stark
contrast
ishig
associ
japan
report
microorgan
ubiquit
pulmonari
lymph
node
commens
found
nonsarcoid
patient
studi
high
posit
result
studi
like
due
either
geographicalethicraci
differ
potenti
contamin
process
perhap
intrigu
find
came
correl
pcr
find
clinic
inform
patient
lymph
node
contain
bacteria
dna
present
also
highli
symptomat
poorerprognosi
radiograph
stage
ii
find
moreov
median
year
followup
bacteri
dnaposit
patient
still
highli
symptomat
strike
correl
strongli
suggest
demonstr
bacteri
dna
pcr
lymph
node
initi
present
advers
prognost
factor
make
unlik
patient
spontan
remiss
mani
pathogen
microorgan
mycobacterium
lepra
leprosi
coronavirus
sever
acut
respiratori
syndrom
grown
directli
cultur
slow
grow
difficult
cultur
astropheryma
whippelii
whippl
diseas
instanc
detect
identif
reli
molecular
mechan
pcr
use
studi
nevertheless
molecular
approach
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
imbed
process
postembed
handl
process
paraffin
block
howev
studi
thirti
control
lymph
node
process
ident
manner
bacteri
dna
detect
significantli
less
sarcoidosi
node
p
suggest
contamin
unlik
account
find
note
sarcoidosi
lymph
node
posit
mycobacteria
studi
less
year
old
evalu
pcr
use
fresh
lymph
node
tissu
like
drake
associ
found
pcr
posit
mycobacteria
speci
may
much
higher
rate
posit
bacteri
dna
result
particularli
mycobacteria
studi
sarcoidosi
granulomat
diseas
primarili
involv
lung
lymph
node
organ
appear
result
exuber
cell
macrophag
immunolog
respons
continu
present
poorli
degrad
antigen
numer
noninfect
agent
implic
base
epidemiolog
basi
none
stood
scrutini
focu
last
two
decad
infect
agent
might
trigger
sarcoidosi
strongest
suspect
found
mycobacteria
famili
common
commens
propionibacterium
acn
like
classic
tuberculosi
peopl
infect
mycobacterium
tuberculosi
remain
remiss
without
treatment
sarcoidosi
also
spontan
remiss
rate
without
treatment
one
may
specul
similar
tuberculosi
immun
system
initi
respons
trigger
microorgan
success
erad
agent
immun
respons
subsid
persist
progress
sarcoidosi
organ
remain
viabl
perpetu
destruct
immun
respons
symptomat
sarcoidosi
usual
treat
variou
antiinflammatori
immunosuppress
agent
corticosteroid
methotrex
tnfinhibitor
similar
immunolog
abnorm
treatment
anoth
debilit
granulomat
diseas
crohn
diseas
strike
granulomat
ileiti
crohn
suspect
mani
investig
result
chronic
infect
oblig
intracellular
microorgan
mycobacterium
avium
subspeci
paratuberculosi
map
known
caus
granulomat
ileiti
cattl
rumin
call
john
diseas
although
classic
treatment
crohn
diseas
immunosuppress
agent
like
sarcoidosi
mani
recent
studi
suggest
much
effect
treatment
less
side
effect
may
tripl
antibiot
regimen
gear
toward
put
trigger
agent
map
fact
mani
field
suspect
intracellular
organ
map
resid
macrophag
impair
normal
autophagi
would
usual
erad
organ
agent
enhanc
autophagi
current
human
trial
may
prove
effect
along
antibiot
crohn
diseas
antibacterialantimycobacteri
regimen
use
crohn
diseas
alter
natur
histori
sarcoidosi
chronic
symptomat
patient
sixti
year
ago
number
small
trial
use
classic
antitubercul
drug
isoniazid
streptomycin
cortison
publish
discourag
result
howev
atyp
mycobacteria
rather
tuberculosi
like
one
etiolog
agent
sarcoidosi
almost
resist
standard
antituberculosi
agent
isoniazid
organ
proprionibacterium
acn
perhap
cellwal
defici
lform
bacteria
trigger
perpetu
sarcoidosi
individu
standard
antitubercul
drug
would
also
ineffect
tetracyclin
deriv
minocyclin
doxycyclin
well
antimalari
drug
chloroquin
shown
quit
effect
treat
cutan
sarcoidosi
last
three
decad
numer
studi
examin
everi
aspect
sarcoidosi
includ
dysfunct
immun
respons
primari
therapi
immun
suppress
variou
form
treat
symptom
seem
alter
natur
proprionibacterium
acn
molecular
studi
like
warrant
perhap
follow
lead
crohn
diseas
gastroenterologist
dr
sengupta
contribut
data
acquisit
analysi
interpret
revis
articl
prior
public
contribut
data
acquisit
analysi
interpret
dr
sandin
contribut
concept
hypothesi
delin
design
studi
revis
articl
prior
public
addit
data
avail
author
report
potenti
conflict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
materi
result
work
support
resourc
use
facil
sarcoidosi
common
yet
incur
chronic
granulomat
diseas
unknown
etiolog
treat
nonspecif
antiinflammatori
andor
immunosuppress
drug
persist
symptomat
patient
worsen
despit
treatment
disabl
potenti
fatal
clinic
cours
propos
sarcoidosi
result
chronic
granulomat
infect
treatabl
pathogen
certain
suscept
individu
much
like
granulomat
ileiti
crohn
diseas
show
encourag
respons
multidrug
antimicrobi
therapi
casecontrol
retrospect
studi
correl
clinic
outcom
presenc
detect
bacteri
dna
sarcoidosi
lymph
node
versu
control
lymph
node
entir
group
sarcoidosi
patient
significantli
detect
bacteri
dna
control
patient
lymph
node
nevertheless
molecular
approach
bacteri
detect
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
imbed
process
postembed
handl
process
paraffin
block
also
mere
physic
presenc
bacteri
dna
lymph
node
prove
diseas
caus
microorgan
addit
number
lymph
node
posit
bacteri
dna
may
significantli
underestim
tendenc
formalinfix
paraffin
embed
process
breakdown
prokaryot
dna
peer
review
http
bmjopenbmjcomsiteaboutguidelinesxhtml
fundament
patholog
abnorm
diseas
format
noncas
epitheliod
granuloma
usual
confin
poorli
solubl
foreign
materi
simpli
remov
singl
phagocyt
cell
key
featur
sarcoidosi
activ
cell
differenti
type
helper
cell
secret
augment
macrophag
amplifi
local
cellular
immun
respons
granulomat
inflamm
interfer
local
tissu
homeostasi
lead
organ
impair
sinc
sarcoidosi
primarili
involv
lung
eye
skin
attent
focus
airborn
environment
antigen
might
trigger
presum
hypersensit
respons
cellmedi
cellular
immun
respons
similar
granulomat
respons
seen
varieti
infecti
agent
includ
mycobacteria
parasit
schistosoma
fungi
coccidiomycosi
earli
studi
report
associ
noninfect
agent
includ
beryllium
zirconium
aluminum
woodburn
stove
tree
pollen
clay
soil
talc
insecticid
inorgan
particl
moldi
environ
none
theoret
caus
endur
also
severalfold
increas
incid
sarcoidosi
occur
sibl
f
r
p
e
e
r
r
e
v
e
w
n
l
parent
well
consist
strong
associ
specif
gene
product
class
class
ii
hla
antigen
may
add
famili
connect
although
infecti
agent
cultur
directli
sarcoidosi
tissu
clinic
immunolog
characterist
disord
provid
strongest
support
microbi
etiolog
least
patient
explor
possibl
infecti
caus
patient
seen
moffitt
cancer
center
correl
clinic
present
longterm
followup
sarcoidosi
patient
presenc
bacteri
dna
archiv
surgicallyresect
mediastin
lymph
node
result
sarcoidosi
node
compar
control
lymph
node
resect
time
lung
surgeri
nodeneg
stage
nonsmal
cell
lung
cancer
patient
tissu
clinic
data
casecontrol
studi
obtain
approv
moffitt
cancer
center
scientif
review
committe
protocol
mcc
univers
south
florida
irb
protocol
search
moffitt
cancer
center
surgic
patholog
databas
januari
inhibit
rule
check
abil
exogen
ad
target
dna
amplifi
pcr
mix
contain
dna
extract
clinic
specimen
gene
fragment
amplifi
previous
describ
gene
amplifi
use
primer
rna
polymeras
subunit
gene
rpob
amplifi
use
mf
mr
primer
amplifi
product
sequenc
use
primari
variabl
compar
sarcoidosi
control
patient
number
patient
group
bacteri
dna
found
lymph
node
two
proport
test
compar
independ
proport
small
sampl
size
use
compar
result
two
group
addit
odd
ratio
confid
interv
calcul
numer
data
express
mean
standard
deviat
comorbid
asthma
coronari
arteri
diseas
diabet
mellitu
hypertens
one
gout
hypothyroid
eczema
fibromyalgia
crohn
diseas
malign
extrem
common
half
current
prior
tumor
find
note
previous
other
malign
prior
time
present
breast
melanoma
uterin
sarcoma
tonsil
ovari
adren
colon
hodgkin
lymphoma
chest
long
object
casecontrol
studi
twofold
evalu
sterilelyresect
lymph
node
document
sarcoidosi
patient
presenc
bacteri
dna
molecular
method
b
correl
result
clinic
characterist
patient
expect
molecular
test
use
pcr
demonstr
onethird
sarcoidosi
patient
evid
bacteri
dna
node
indic
either
past
current
involv
microorgan
percentag
bacteri
dnaposit
specimen
fall
rang
found
numer
prior
publish
studi
last
two
decad
use
variou
methodolog
rang
posit
tabl
furthermor
atyp
mycobacteria
proprionibacterium
acn
repres
almost
dna
identifi
also
consist
find
multipl
prior
studi
tabl
addit
identifi
one
skin
mucou
membran
organ
corynebacterium
propinquum
one
aerob
gram
neg
bacillu
duganella
zoogloeoid
usual
found
aqueou
environ
interestingli
latter
patient
duganella
zoogloeoid
asbesto
technician
origin
tropic
haiti
disclaim
find
dna
microorgan
lymph
node
tell
us
whether
viabl
organ
present
whether
caus
granulomat
reaction
similar
prior
publish
studi
summar
tabl
differ
strongli
suggest
demonstr
bacteri
dna
sarcoidosi
lymph
f
r
p
e
e
r
r
e
v
e
w
n
l
node
real
find
studi
prior
publish
studi
process
contamin
therefor
point
microorgan
potenti
contributor
genesi
diseas
addit
propionibacterium
acn
dna
found
control
lymph
node
studi
stark
contrast
ishig
associ
japan
report
microorgan
ubiquit
pulmonari
lymph
node
commens
found
nonsarcoid
patient
studi
high
posit
result
studi
like
due
either
geographicalethicraci
differ
potenti
contamin
process
perhap
intrigu
find
came
correl
pcr
find
clinic
inform
patient
lymph
node
contain
bacteria
dna
present
also
highli
symptomat
poorerprognosi
radiograph
stage
ii
find
moreov
median
year
followup
bacteri
dnaposit
patient
still
highli
symptomat
strike
correl
strongli
suggest
demonstr
bacteri
dna
pcr
lymph
node
initi
present
advers
prognost
factor
make
unlik
patient
spontan
remiss
specimen
note
sarcoidosi
lymph
node
posit
mycobacteria
studi
less
year
old
evalu
pcr
use
fresh
lymph
node
tissu
like
drake
associ
found
pcr
posit
mycobacteria
speci
may
much
higher
rate
posit
bacteri
dna
result
particularli
mycobacteria
studi
sarcoidosi
granulomat
diseas
primarili
involv
lung
lymph
node
organ
appear
result
exuber
cell
macrophag
immunolog
respons
continu
present
poorli
degrad
antigen
numer
noninfect
agent
implic
base
epidemiolog
basi
none
stood
scrutini
focu
last
two
decad
infect
agent
might
trigger
sarcoidosi
strongest
suspect
found
mycobacteria
famili
common
commens
propionibacterium
acn
like
classic
tuberculosi
peopl
infect
mycobacterium
tuberculosi
remain
remiss
without
treatment
sarcoidosi
also
spontan
remiss
rate
without
treatment
one
may
specul
similar
tuberculosi
immun
system
initi
respons
trigger
microorgan
success
erad
agent
immun
respons
subsid
persist
progress
sarcoidosi
organ
remain
viabl
perpetu
destruct
immun
respons
although
classic
treatment
crohn
diseas
immunosuppress
agent
like
sarcoidosi
mani
recent
studi
suggest
much
effect
treatment
less
side
effect
may
tripl
antibiot
regimen
gear
toward
put
trigger
agent
map
fact
mani
field
suspect
intracellular
organ
map
resid
macrophag
impair
normal
autophagi
would
usual
erad
organ
agent
enhanc
autophagi
current
human
trial
may
prove
effect
along
antibiot
crohn
diseas
antibacterialantimycobacteri
regimen
use
crohn
diseas
alter
natur
histori
sarcoidosi
chronic
symptomat
patient
sixti
year
ago
number
small
trial
use
classic
antitubercul
drug
isoniazid
streptomycin
cortison
publish
discourag
result
howev
atyp
mycobacteria
rather
tuberculosi
like
one
etiolog
agent
sarcoidosi
almost
resist
standard
antituberculosi
agent
isoniazid
organ
proprionibacterium
acn
perhap
cellwal
defici
lform
bacteria
trigger
perpetu
sarcoidosi
individu
standard
antitubercul
drug
would
also
ineffect
tetracyclin
deriv
minocyclin
doxycyclin
well
antimalari
drug
chloroquin
shown
quit
effect
treat
cutan
sarcoidosi
minocyclin
produc
complet
respons
twothird
case
although
debat
whether
antimicrobi
effect
immunomodul
effect
attent
recent
turn
random
sarcoidosi
treatment
trial
variou
anti
minocyclin
produc
complet
respons
twothird
case
although
debat
whether
antimicrobi
effect
immunomodul
effect
last
three
decad
numer
studi
examin
everi
aspect
sarcoidosi
includ
dysfunct
immun
respons
primari
therapi
immun
suppress
variou
form
treat
symptom
seem
alter
natur
histori
diseas
dozen
studi
tabl
dr
smith
contribut
concept
hypothesi
delin
design
studi
data
acquisit
analysi
interpret
revis
articl
prior
public
dr
sengupta
contribut
data
acquisit
analysi
interpret
revis
articl
prior
public
contribut
data
acquisit
analysi
interpret
dr
sandin
contribut
concept
hypothesi
delin
design
studi
revis
articl
prior
public
data
share
addit
data
avail
financialnonfinanci
disclosur
author
report
potenti
conflict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
introduct
backgroundrational
page
explain
scientif
background
rational
investig
report
object
page
state
specif
object
includ
prespecifi
hypothes
studi
design
present
key
element
studi
design
earli
paper
set
page
describ
set
locat
relev
date
includ
period
recruit
exposur
followup
data
collect
particip
page
cohort
studyg
elig
criteria
sourc
method
select
particip
describ
method
followup
casecontrol
studyg
elig
criteria
sourc
method
case
ascertain
control
select
give
rational
choic
case
control
crosssect
studyg
elig
criteria
sourc
method
select
particip
report
analys
doneeg
analys
subgroup
interact
sensit
analys
key
result
summaris
key
result
refer
studi
object
discuss
limit
studi
take
account
sourc
potenti
bia
imprecis
discuss
direct
magnitud
potenti
bia
interpret
give
cautiou
overal
interpret
result
consid
object
limit
multipl
analys
result
similar
studi
relev
evid
generalis
conclus
section
discuss
generalis
extern
valid
studi
result
fund
titl
page
give
sourc
fund
role
funder
present
studi
applic
origin
studi
present
articl
base
give
inform
separ
case
control
casecontrol
studi
applic
expos
unexpos
group
cohort
crosssect
studi
note
explan
elabor
articl
discuss
checklist
item
give
methodolog
background
publish
exampl
transpar
report
strobe
checklist
best
use
conjunct
articl
freeli
avail
web
site
plo
medicin
http
wwwplosmedicineorg
annal
intern
medicin
http
wwwannalsorg
epidemiolog
http
wwwepidemcom
inform
strobe
initi
avail
wwwstrobestatementorg
peer
review
http
bmjopenbmjcomsiteaboutguidelinesxhtml
